Semaglutide Pilot
Brief description of study
Aim: To conduct a pilot open-label study of semaglutide in lung transplant candidates with obesity. - We will get an estimate of recruitment fraction and retention on study drug. - We will determine preliminary effect estimates of change in weight, percent body fat, skeletal muscle mass, and circulating levels of leptin, c-reactive protein, glycated hemoglobin, and free fatty acids. - We will evaluate medication tolerability and side effects over 12 weeks of therapy. - We will determine feasibility of a protocol for titrating semaglutide to a target weight. Medication tolerability and side effects over 12 weeks of therapy. The primary outcome will be the number of subjects who remain on therapy at 12 weeks. Change in weight, percent body fat, skeletal muscle mass, and circulating levels of leptin, c-reactive protein, glycated hemoglobin, and free fatty acids after 12 weeks of therapy. We will evaluate recruitment fraction and retention on study drug. We will determine feasibility of a protocol for titrating semaglutide to a target weight.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
